Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00137748 · ClinicalTrials.gov registry record · Phase 2
Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients
A Phase 2 study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00137748 is a Phase 2 study that has completed, run by The Cleveland Clinic. The registered enrollment target is 50 participants.
The verdict
NCT00137748, a Phase 2 study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a randomized controlled trial of CMV-Ig in lung transplant recipients at the Cleveland Clinic Foundation who are hypogammaglobulinemic.
Interventions
- DRUG CMV-Ig
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2001-01 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00137748
The ClinicalTrials.gov registry entry for NCT00137748 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CMV-Ig is the first listed.
NCT00137748 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00137748 about?
NCT00137748 is a clinical study titled "Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients". This is a randomized controlled trial of CMV-Ig in lung transplant recipients at the Cleveland Clinic Foundation who are hypogammaglobulinemic.
What is the current status of trial NCT00137748?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2001-01. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00137748?
The interventions under investigation include: CMV-Ig (DRUG).
Who is sponsoring clinical trial NCT00137748?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.